
Alto Neuroscience, Inc.
100
Recent developments highlight Alto Neuroscience's clinical progress, capital raising activities, and market recognition.
- Alto Neuroscience was noted among biotech stocks reaching 52-week highs, reflecting positive market interest [N1].
- In July 2026, the company priced a direct offering worth $100 million at $26.48 per share to support ongoing operations and clinical development [N2].
- The company continues to advance multiple clinical trials, including Phase 2b studies for ALTO-207, ALTO-300, and ALTO-100, with topline data anticipated in 2027 [S2].
- Analyst coverage initiated by BTIG with a buy recommendation and maintained buy/outperform ratings by Baird and Jefferies in late 2025 indicate sustained analyst interest [N5][N7][N8].
- Market commentary in late 2025 and 2026 highlights Alto Neuroscience's relative outperformance among medical and biotech stocks [N6].
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, personalized treatments for psychiatric and neurological disorders. Utilizing its proprietary Precision Psychiatry Platform, the company aims to improve treatment outcomes by targeting patient biology and brain processes. Its pipeline includes seven clinical-stage product candidates addressing major depressive disorder, bipolar depression, treatment resistant depression, schizophrenia, and Parkinson's disease. Key candidates include ALTO-207, a fixed-dose combination targeting TRD; ALTO-300, an adjunctive treatment for MDD characterized by EEG biomarkers; and ALTO-100 for bipolar depression. The company has ongoing Phase 2 and Phase 3 clinical trials and plans to advance its pipeline through regulatory and clinical milestones. Alto Neuroscience has not generated revenue from product sales and funds operations primarily through equity financings and debt. As of September 30, 2026, it held substantial cash reserves and reported net losses consistent with its clinical-stage status [S2].
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company developing personalized psychiatric and neurological treatments through its Precision Psychiatry Platform. The company has a diversified pipeline of seven clinical-stage candidates targeting disorders including major depressive disorder, bipolar depression, treatment resistant depression, schizophrenia, and Parkinson's disease. It has ongoing Phase 2 and Phase 3 clinical trials, with key programs such as ALTO-207 and ALTO-300 advancing. Financially, the company reported net losses and an accumulated deficit as of September 30, 2026, but maintains a strong liquidity position with over $319 million in cash and equivalents and a high current ratio. Funding has been supported by equity offerings and debt. The company’s financial statements are audited and its accounting policies involve significant estimates related to R&D expenses and stock-based compensation. Recent analyst coverage and news highlight positive market interest and stock performance [S1][S2][N1][N2][N5]. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Alto Neuroscience has a broad and diversified clinical pipeline addressing significant unmet needs in psychiatry and neurology, with multiple candidates in Phase 2 and planned Phase 3 trials. Its Precision Psychiatry Platform enables targeted development based on patient biology and biomarkers, potentially improving efficacy and tolerability. Positive clinical signals, such as those observed with ALTO-207 and ALTO-101, and ongoing biomarker-driven trials may support differentiation. The company’s strong liquidity position and recent capital raises provide resources to advance clinical programs. Continued clinical progress and regulatory alignment could enhance its development prospects [S2][N2].
As a clinical-stage biopharmaceutical company, Alto Neuroscience faces risks including clinical trial failures, regulatory hurdles, and the absence of product revenue. The company has incurred significant net losses and an accumulated deficit, reflecting ongoing operating expenses without commercial sales. Its reliance on equity and debt financing introduces funding risk, and future capital needs may impact operations. Clinical programs may encounter delays or fail to demonstrate efficacy or safety. The company’s valuation and stock performance may be sensitive to clinical and regulatory developments. Market competition and evolving scientific understanding also pose challenges [S1][S2].
Alto Neuroscience's moat is based on its proprietary Precision Psychiatry Platform, which integrates neurobiological insights to develop personalized psychiatric treatments. The company’s diversified pipeline of clinical-stage candidates targeting high-need therapeutic areas, combined with biomarker-driven patient selection strategies, may provide differentiation in a competitive biopharmaceutical landscape. Its focus on novel mechanisms and combination therapies, supported by clinical data and biomarker validation, contributes to potential competitive advantages. However, as a clinical-stage company without approved products, its moat is contingent on successful clinical development and regulatory approvals [S2].
• Clinical Development Risk: The company’s product candidates are in clinical stages and may fail to demonstrate safety or efficacy, leading to delays or termination of development programs.
• Funding Risk: Alto Neuroscience relies on external financing to fund operations and clinical trials; inability to secure adequate funding could impair development and operations.
• Regulatory Risk: Obtaining regulatory approvals is uncertain and may require extensive data and time; failure to obtain approvals would prevent commercialization.
• Operational Risk: The company’s ability to execute clinical trials, manage costs, and scale operations affects its development progress and financial condition.
• Market and Competitive Risk: Competition from other biopharmaceutical companies and evolving treatment standards may impact the company’s market opportunities and valuation.
Business trends: Advancement of multiple clinical-stage candidates targeting psychiatric and neurological disorders with biomarker-driven approaches.
Execution milestones: Completion and reporting of Phase 2b and initiation of Phase 3 clinical trials for key candidates such as ALTO-207 and ALTO-300; capital raising to support development.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, funding availability, and competitive pressures inherent to clinical-stage biopharmaceutical companies.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized treatments for psychiatric and neurological disorders using its proprietary Precision Psychiatry Platform [S2].
- The company’s pipeline includes seven clinical-stage product candidates targeting major depressive disorder (MDD), bipolar depression (BPD), treatment resistant depression (TRD), schizophrenia, and Parkinson’s disease [S2].
- ALTO-207 is a fixed-dose combination of pramipexole and ondansetron designed to treat TRD; a Phase 2b randomized, double-blind, placebo-controlled trial was initiated in April 2026 with approximately 178 adults, with topline data anticipated in the second half of 2027 [S2].
- Plans include initiating adjunctive and monotherapy Phase 3 trials for ALTO-207 in TRD patients, with development accelerated as of July 2026 [S2].
- ALTO-300 (agomelatine) is being evaluated in a Phase 2b trial as adjunctive treatment for MDD characterized by an EEG biomarker, with approximately 200 biomarker-positive patients enrolled; topline data expected in the first half of 2027 [S2].
- ALTO-100 is in a Phase 2b trial for bipolar depression as adjunctive treatment, targeting approximately 200 patients, with topline data expected mid-2027 [S2].
- ALTO-101, evaluated in a Phase 2 proof-of-concept trial for cognitive impairment associated with schizophrenia, did not meet primary endpoints but showed directional improvements in EEG measures and favorable tolerability; a modified-release formulation with improved profile is under consideration for partnering [S2].
- ALTO-203, an oral histamine H3 inverse agonist, showed positive pharmacodynamic results in a Phase 2 exploratory trial in MDD patients with anhedonia, with ongoing evaluation of indications [S2].
- ALTO-202 (NMDA receptor antagonist) and ALTO-208 (fixed-dose pramipexole and aprepitant for Parkinson’s disease) are in planning or early development stages [S2].
- The company has not generated revenue from product sales and has incurred recurring losses since inception, with net losses of $25.1 million for the three months ended September 30, 2026, and an accumulated deficit of $280.6 million as of that date [S2].
- As of September 30, 2026, Alto Neuroscience held $319.3 million in cash and equivalents, with current assets of $323.2 million and current liabilities of $17.8 million, resulting in a strong current ratio of 18.12 and cash ratio of 17.9 [S2].
- The company funds operations primarily through equity financings, including a $100 million direct offering priced at $26.48 per share in July 2026, and borrowings under a loan and security agreement [N2][S2].
- The company’s financial statements are audited by Deloitte & Touche LLP, with no material misstatements noted as of December 31, 2025 [S1].
- Alto Neuroscience is classified as an emerging growth company and smaller reporting company, with certain scaled disclosure exemptions [S1].
- The company’s critical accounting policies include estimates for accrued research and development expenses and stock-based compensation, with significant judgment applied in valuation and expense recognition [S1].
- Recent news highlights include Alto Neuroscience being mentioned among biotech stocks at 52-week highs and coverage initiation by BTIG with buy recommendation [N1][N5].
- Multiple analyst firms have maintained buy or outperform recommendations on Alto Neuroscience in late 2025 [N5][N7][N8].
Generated 2026-11-11
- S1 | 2026-03-16 | 10-K
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-08-07 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-dcth-22-q2-results-anro-coag-mnpr-nrix
- N2 | 2026-07-15 | www.nasdaq.com | Alto Prices Direct Offering Worth $100 Mln At $26.48 Per Share | https://www.nasdaq.com/articles/alto-prices-direct-offering-worth-100-mln-2648-share
- N3 | 2026-04-06 | www.nasdaq.com | Stocks Recover on Hopes Strait of Hormuz Could Soon Reopen | https://www.nasdaq.com/articles/stocks-recover-hopes-strait-hormuz-could-soon-reopen
- N4 | 2026-04-02 | www.nasdaq.com | Stocks Pare Losses on Hormuz Report | https://www.nasdaq.com/articles/stocks-pare-losses-hormuz-report
- N5 | 2025-11-17 | www.nasdaq.com | BTIG Initiates Coverage of Alto Neuroscience (ANRO) with Buy Recommendation | https://www.nasdaq.com/articles/btig-initiates-coverage-alto-neuroscience-anro-buy-recommendation
- N6 | 2025-11-14 | www.nasdaq.com | Is Alto Neuroscience, Inc. (ANRO) Outperforming Other Medical Stocks This Year? | https://www.nasdaq.com/articles/alto-neuroscience-inc-anro-outperforming-other-medical-stocks-year
- N7 | 2025-11-14 | www.nasdaq.com | Baird Maintains Alto Neuroscience (ANRO) Outperform Recommendation | https://www.nasdaq.com/articles/baird-maintains-alto-neuroscience-anro-outperform-recommendation-0
- N8 | 2025-11-13 | www.nasdaq.com | Jefferies Maintains Alto Neuroscience (ANRO) Buy Recommendation | https://www.nasdaq.com/articles/jefferies-maintains-alto-neuroscience-anro-buy-recommendation
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


